The present invention relates to a genetically modified rodent comprising a nucleic acid sequence encoding human CD22, or (a) fragment(s) thereof, in its genome. The present invention further relates to methods of identifying an agent capable of treating diseases associated with dysregulated B lymphocytes as well as a method of testing the safety of an agent for anti-human CD22 therapy, based on the genetically modified rodent of the invention.
